# Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse in Triple Negative Breast Cancer Patients

> **NCT04438681** · — · ACTIVE_NOT_RECRUITING · sponsor: **Centre Jean Perrin** · enrollment: 90 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04438681
- **Lead sponsor:** Centre Jean Perrin
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-11-27
- **Primary completion:** 2026-11-09
- **Final completion:** 2029-11-09
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04438681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04438681, "Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse in Triple Negative Breast Cancer Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04438681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*